Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly? - Investor's Business Daily
AI Summary1 min read
TL;DR
Pfizer's experimental obesity drug, Metsera, showed promising mid-stage trial results with up to 12.3% weight loss as a monthly treatment, but Pfizer stock dipped amid comparisons to Lilly's offerings.
Tags
Pfizerobesity drugMetseraclinical trialweight loss
- Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly? Investor's Business Daily
- Pfizer stock dips on Metsera mid-stage trial results Axios
- Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial CNBC
- Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial Reuters
- Pfizer unveils data on Metsera drug statnews.com